The leaked internal chat communications of the Black Basta ransomware group offer an unprecedented view into how cybercriminals operate, plan attacks, and ...
If 2023 was the year of shock and 2024 was the year of experimentation, 2025 marks the moment the corporate world finally accepted that artificial intelligence is not just a novelty—it is the new ...
It was Friday afternoon, and I'd just hit send on my weekly report to Amazon's Retail vice presidents, detailing what the Global Merchandising team I'd created had accomplished that week. I was 38, ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...
Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...
GameSpot may get a commission from retail offers. Earlier this month, Call of Duty: Black Ops 7 players called out the apparent use of AI in the game, especially the "Ghibli-style" Calling Cards.
Call of Duty Black Ops 7 is the latest high-profile game to confirm that it uses generative AI for some of its in-game assets, according to a disclosure on its Steam page. After similar disclosures ...
Investors in Recursion (NASDAQ: RXRX) seemed only mildly fazed by Wednesday’s series of company announcements. The artificial intelligence (AI)-based drug developer’s stock barely moved on Wednesday, ...
Recursion Pharmaceuticals has designated its top research executive, Najat Khan, to succeed co-founder Chris Gibson as president and chief executive of the clinical-stage biotechnology company, ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback